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Despite efficient combination of the antiretroviral therapy (cART), which significantly
decreased mortality and morbidity of HIV-1 infection, a definitive HIV cure has not
been achieved. Hidden HIV-1 in cellular and anatomic reservoirs is the major hurdle
toward a functional cure. Microglial cells, the Central Nervous system (CNS) resident
macrophages, are one of the major cellular reservoirs of latent HIV-1. These cells are
believed to be involved in the emergence of drugs resistance and reseeding peripheral
tissues. Moreover, these long-life reservoirs are also involved in the development
of HIV-1-associated neurocognitive diseases (HAND). Clearing these infected cells from
the brain is therefore crucial to achieve a cure. However, many characteristics of microglial
cells and the CNS hinder the eradication of these brain reservoirs. Better understandings
of the specific molecular mechanisms of HIV-1 latency in microglial cells should help
to design new molecules and new strategies preventing HAND and achieving HIV
cure. Moreover, new strategies are needed to circumvent the limitations associated to
anatomical sanctuaries with barriers such as the blood brain barrier (BBB) that reduce
the access of drugs.
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INTRODUCTION
Since the introduction of the combination antiretroviral therapy (cART) in 1996 the fatal evolution
of the HIV-1 infection has stopped and became a chronic disease. However, despite continual
efforts definitive cure has not been achieved. This is mainly due to the lack of efficient vaccination
and to the existence of viral reservoirs. Indeed, as soon as the treatment is interrupted, a viral
rebound is observed within a couple of weeks and viremia is comparable to the one encountered
before the introduction of cART (Davey et al., 1999; García et al., 1999; Mata et al., 2005).
Moreover, with ultrasensitivemethods, we can still notice a residual viremia in patients under cART
(Dornadula et al., 1999; Bouchat et al., 2016). The main reservoirs are the resting CD4+ T cells
but we have now enough evidence which argues for the existence of many other cell reservoirs
such as hematopoietic stem cells, dendritic cells, microglial cells and cells from the monocyte-
macrophage lineage (reviewed in Marcello, 2006; García et al., 2018; Sung and Margolis, 2018).
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In addition, some of these reservoirs are found in sanctuaries
such as the genital tract, the adipose tissue, the bone marrow
and the brain. Targeting the infected cells in these reservoirs
is even more difficult (Sadowski and Hashemi, 2019). The
brain for instance constitutes a typical anatomical site, which
has poor drug penetration and reduced immune surveillance
due to the blood brain barrier (BBB). As a consequence, the
genetical information exchange of the virus confined in the brain
and other compartments such as the blood is poor (Canestri
et al., 2010; Dahl et al., 2014). The measureable pool of latently
infected, resting CD4+ T cells does not account fully for the
early rebounding plasma HIV-1. It has been shown that the
rebounding HIV-1 was genetically different suggesting that these
viruses came from other cell reservoirs (Chun et al., 2000).
In addition, the result of recent phylogenetic studies is in
favor of other physiological observations suggesting that HIV-
1 production in the brain is associated with the emergence
of virus resistance (Smit et al., 2004; Strain et al., 2005) and
with HIV-1 associated neurocognitive disease (HAND) (Salemi
et al., 2005; Lamers et al., 2010). Up to 50% of patients under
cART with undetectable virus in the blood suffer of less severe
forms of HAND (Eggers et al., 2017). The pathogenesis of
HAND is not fully understood but appears to be multifactorial:
drug neurotoxicity of the cART, HIV replication in the central
nervous system (CNS) from quiescent/latent infected cells,
CNS inflammation and co-infection with other viruses such
as hepatitis C virus (reviewed in Sutherland and Brew, 2018).
Indeed production of newly synthesized viral protein such as Tat
or gp120 from infected cells might lead to direct neural injury
(reviewed in Rao et al., 2014). Recent reports described new
mechanisms for HIV-1 Tat-mediated microglial inflammation
which involves a novel miRNA-34a- NOD-like receptor C5
(NLRC5)-NFκB signaling axis or activation of the methyl CpG
binding protein 2 (MEPC2)-STAT3 axis (Periyasamy et al.,
2018, 2019). Activation by Tat of the microglial nucleotide-
binding domain leucin-rich repeat and pyrin-containing receptor
3 (NLRP3) inflammasome also lead to the occurrence of
neuroinflammation (Chivero et al., 2017). Indirect impact on the
integrity of neurons is also observed during sustained chronic
inflammation induced by secreting perivascular macrophages
or microglial cells (reviewed in Eggers et al., 2017). Following
activation these immune cells release neurotoxic host factors
such as pro-inflammatory cytokines (TNFα, IFNα, IL6, IL8,
IL1β) (Nolting et al., 2012; Zhou et al., 2016; Abassi et al.,
2017) and chemokines (CCL2 and CCL5) (Woods et al., 2006;
Zhou et al., 2016). All together these indirect evidences strongly
support the existence of cellular reservoirs in the CNS. At
least, three different types of infected cells have been described
in the CNS referred as a compartment (Bednar et al., 2015):
astrocytes, cells from the monocyte lineage (Wong et al., 2019)
and microglial cells (Joseph et al., 2015). These putative true
reservoirs are established very early during HIV-1 infection
(within 3 to 5 days following infection) (Koenig et al., 1986;
Whitney et al., 2014). It is well-documented that infection of
the CNS results from transmigration of infected CD4+ cells
(reviewed in Williams et al., 2012) and of infected monocytes
across the BBB (Williams et al., 2012). However, these infected
cells entering the CNS do not constitute an HIV reservoir
since they have a very short half-life. Instead they will be the
source of the infection of three long lived cell types: astrocytes,
perivascular macrophages and microglial cells. Whether or not
these cells constitute true cell reservoirs is still debated (Gray
et al., 2014; Al-Harti et al., 2018; Vanhamel et al., 2019). Criteria
for a cell reservoir are the followings: (i) presence of HIV-
1 DNA integrated in the host genome of long lived cells, (ii)
existence of mechanisms which allow the virus to persist for
long period in latent cells which include mechanisms allowing
establishment and maintenance of a latent infection and (iii)
formation of replication-competent particles following activation
of the reservoirs (Eisele and Siliciano, 2012). Two criteria of
a true latency reservoir have been described in these cells: the
presence of HIV-1 integrated DNA in long lived cells and the
existence of mechanisms which allow the virus to persist for
long period in latent cells (Blankson et al., 2002). On the other
hand, it cannot be explored whether these cells can produce
replication-competent viruses in human due to ethical and
technical problems.
The astrocyte is the most abundant infected cell type in
the CNS with up to 10–20% having HIV-1 DNA in the cell
genome (Churchill et al., 2009). However a recent study using
sensitive methods detected HIV-1 in brain macrophages and
microglial cells but not in astrocytes (Ko et al., 2019). Moreover,
the infection appears to be non-productive. Thus they might not
constitute a true viral reservoir for HIV-1 (Gorry et al., 2003).
On the contrary there is evidence that both macrophages and
microglial cells are susceptible to HIV-1 infection and support
productive infection (reviewed in Joseph et al., 2015). As already
mentioned, the productive infection in these later cells in the
CNS has been associated with HAND in humans and in animal
models such as the macaques. Therefore, both macrophages and
microglial cells can be considered as true reservoirs in the brain.
However, their relative importance is not the same due to their
differences in size and constitution in the brain. Themacrophages
are bone marrow-derived with a half-life of months and they
do not undergo cell division (Koppensteiner et al., 2012). They
are repopulated from monocytes crossing the BBB. Under a
very efficient cART or by using therapeutic strategies preventing
the specific subset of infected monocytes to cross the BBB we
might expect in the future to drastically decrease this reservoir
in the brain. The microglial cells originate from erythromyeloid
progenitors in the yolk sac during embryogenesis and colonize
the forming CNS (Kierdorf et al., 2013). They constitute therefore
the main resident cells of the brain which can serve as brain
macrophages. Due to their long half-life of years they constitute
a very stable population (Réu et al., 2017). In addition unlike
macrophages they can undergo cell division enabling HIV-1 to
persist in the brain (Lawson et al., 1992). Moreover, a recent
report suggests that microglial cells are highly susceptible to HIV-
1 infection (Cenker et al., 2017). Altogether, the microglial cells
might constitute one of the main HIV-1 reservoir in the brain.
In the review we will first present microglial cells and
discuss why they might be the main HIV-1 cell reservoirs
in the cART era. We suggest that microglial cells should be
the main target in the brain in order to achieve cure. As a
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prerequisite it is needed to decipher the molecular mechanisms
of the establishment and the maintenance of HIV-1 latency in
these cells. In further section, we will discuss the therapeutic
implications of these mechanisms followed by the discussion of
the challenges facing when targeting microglial cells and how to
circumvent these limitations.
MICROGLIAL CELLS, A KEY PLAYER
DURING THE COURSE OF HIV-1
INFECTION
The Biology of Microglial Cells
Microglial cells constitute the CNS resident innate immune cells
(Bilimoria and Stevens, 2015). They are the most abundant mono
nuclear macrophages which are found in the totality of the brain
parenchyma. These cells appear very early during embryogenesis
and derive from early myeloid precursors in the embryogenic
yolk sac (Gomez Perdiguero et al., 2015; Sheng et al., 2015).
Microglial cells colonize the entire brain parenchyma before the
formation of the BBB and subsist by slow cell division during
life (Gomez Perdiguero et al., 2015). The median rate of human
microglial cell renewal is around 30% per year. In a recent report,
it was estimated that microglial cells are on average 4.2 years old
and most of the cells in the population regenerates throughout
life (Réu et al., 2017). Contrary to the other potentially infected
cells in the brain this slow cell division allows the persistence of
HIV-1 in the brain throughout the life of the patient. Both resting
and activated microglial cells are ramified cells with multiple
branches and processes which contact neurons, astrocytes and
blood vessels (reviewed in Sominsky et al., 2018). Resting cells
are transformed to activated macrophage like state when sensing
a change in their microenvironment (reviewed in Colonna and
Butovsky, 2017). They are also very mobile and rapidly reach
the site of brain damage. When activated, these cells release
many cytokines, chemokines and other neurotoxic proteins.
These secretory factors might contribute to the pathological
neuroinflammation observed in HAND (Hong and Banks, 2015).
Many other diseases have been associated with pathological
neuroinflammation and are described elsewhere (Salter and
Stevens, 2017). Microglial cells express numerous pattern-
recognition receptors (PRRs) such as TLR1/2, TLR3, and TLR4
(reviewed in Colonna and Butovsky, 2017). Many other immune
receptors are also expressed in microglial cells including CD4+,
chemokine receptors, receptors which regulate the activation
of microglial cells such as Triggering Receptor Expressed on
Myeloid cell 2 (TREM2). These receptors might serve as a marker
of inflammation during the course of HIV-1 infection (Gisslén
et al., 2019). Many receptors for pro-inflammatory factors
(TNFα, IL1β, IL10) and anti-inflammatory factors (IFNα/β) are
also expressed (Lee et al., 2002). Interestingly, released anti-
inflammatory factors transfer signals to the cell interior via
a specific receptor complex to generate an antiviral response
(Taniguchi and Takaoka, 2002). An exhaustive review of the wide
range of immune receptors is described elsewhere (Colonna and
Butovsky, 2017). Apart its function in immune surveillance to
eliminate the microbes, microglial cells can also eliminate dead
cells, redundant synapses, protein aggregates such as amyloid
plaques (reviewed in Colonna and Butovsky, 2017; Salter and
Stevens, 2017; Sominsky et al., 2018). These cells are involved
in several functions of the CNS, including neurogenesis, the
control of synaptic density and connectivity and the regulation
of synaptic plasticity through the release of many cytokines
such as Brain-Derived Neurotrophic Factor (BNDF). Of note
HIV-1 Tat protein can inhibit BNDF by up regulating the
microRNA mir-34a (Santerre et al., 2019). Microglial cells can
also engulf neurotransmitters released in excess and therefore
prevent excitotoxicity and participate in the cross talk between
microglial cells and astrocytes. Due to their multifunction,
any dysfunction in microglia cells will lead to many diverse
diseases including brain aging or neurodegenerative diseases
such as Alzheimer disease, Parkinson disease and amyotrophic
lateral sclerosis. They are also central players in the occurrence
of pathological neuroinflammation observed in patients under
cART. HAND is thought to be related to excessive secretion
of cytokines and chemokines (Yadav and Collman, 2009;
Burdo et al., 2013; Eggers et al., 2017). In a recent study
the gene expression profile in microglial cells from infected
patients under cART with or without HIV encephalitis (HIVE)
has been investigated which showed differential expression of
several classes of genes compared to non-infected patients.
64% of the genes were effected in HIVE positive patients and
24% in HIVE negative patients (Ginsberg et al., 2018). This
report strongly suggests that neuroinflammation, which leads
to neurodegenerative diseases such as HAND, is associated
with microglial impairment. Neuroimaging such as positron
emission tomography (PET) has shown that neuroinflammation
develops even under effective cART (Tavazzi et al., 2014; Vera
et al., 2016). This approach has highlighted the importance
of microglial activation in HIV+ patients under efficient
cART with or without any cognitive impairments. PET also
allows to follow the level of microglial activation by targeting
translocator protein (TSPO) (Sinharay and Hammoud, 2019).
Indeed, upregulation of TSPO during microglial activation is
related to the degree of neuroinflammation (Venneti et al., 2004).
Activation of microglial cells will further lead to the progression
of neurodegenerative diseases by impacting the BBB (reviewed in
da Fonseca et al., 2014; Osipova et al., 2018). Indeed microglial
cells activation modulates tight junctions of endothelial cells of
the BBB (Sumi et al., 2010). Of note, inhibition of microglial
activation by minocycline is associated with preservation of BBB
integrity in vitro and with reduced disruption of the BBB in vivo
(Yenari et al., 2006; Sheng et al., 2018).
In conclusion, microglial cells fulfill several criteria of a brain
reservoir. Most importantly they can subsist for a very long
time in the brain and they can colonize the brain parenchyma.
Contrary to other potential reservoirs in the brain, these cells
divide slowly expanding the viral reservoirs in the brain and thus
allowing virus persistence and reseeding of the blood. They are
also involved in many functions including immune surveillance.
As a consequence, any dysfunction of these cells might explain
the occurrence of HAND.
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Evidence Supporting That Microglial Cells
Are Susceptible to HIV-1 Infection and
They Contribute to the Formation of a Cell
Reservoir in the Brain
It is believed that microglial cell infection arises from
transmigration of infected monocytes occurring very early in
the course of infection. Recently, a specific subset of infected
monocytes which preferentially cross the BBB, the HIV+CD14+
CD16+ monocytes, has been characterized (Veenstra et al.,
2017). These cells express abundantly junctional proteins such
as Junctional Adhesion Molecule-A (JAM-A) and Activated
Leukocyte Cell Adhesion Molecule (ALCAM) and chemokine
receptors CCR2 which help these cells to cross the BBB.
In turn these infected monocytes may infect microglial cells.
Alternatively, but still debated, infected CD4+ T cells migrating
into the brain might be ingested by microglial cells (Murooka
et al., 2012). Although it has not been clearly demonstrated, this
later mechanism could be more efficient to spread the virus than
exposure to the free virus (Baxter et al., 2014). Whatever the
mechanism of infection, it appears that brain microglial cells are
permissive to HIV-1 infection. This is despite high level of the
restriction factor SAM domain and HD domain 1 (SAMHD1)
(Rodrigues et al., 2017). The absence of restriction by SAMDH1
is due to its phosphorylation by the cyclin kinase 1 (CDK1)
which is induced in microglial cells that cycle between G0 to G1
state (Cribier et al., 2013; Mlcochova et al., 2017). There is now
evidence supporting that microglial cells are infected by HIV-1
both in vitro and in vivo (reviewed in Joseph et al., 2015). Previous
studies from autopsy have identified HIV-1 DNA, RNA and
protein in microglial cells (Cosenza et al., 2002; Churchill et al.,
2006). However, it was pointed out that these patients died from
severe form of HAND. A recent study confirmed that microglial
cells are infected in patients whose viral level is suppressed but
died from an HIV-1 unrelated outcome (Ko et al., 2019). In this
study the authors used a unique cohort from the National Neuro
AIDS Tissue Consortium (NTTC) which comprised 16 patients
on cART with well-documented, sustained control of HIV-1.
They used highly specific technology to detect and quantify both
HIV-1 DNA and RNAs at the cellular level. Very interestingly
they showed that both perivascular macrophages and microglial
cells but not astrocytes harbored HIV-1 DNA. In 6 out 16
cases they also found HIV-1 RNA in these cells when HIV-1
RNA was undetectable in the cerebro Spinal Fluid (CSF) and
in the blood. This result strongly argues in favor that virus
production can take place in the CNS. Other studies have also
shown that microglial cells are susceptible to infection in vitro.
Several in vitro models of human microglial cells susceptible of
infection have been developed (Janabi et al., 1995; Nagai et al.,
2001; Garcia-Mesa et al., 2017; Rawat and Spector, 2017; Dello
Russo et al., 2018). Some models for latency have been derived
from these previous models and constitute valuable tools to
study the mechanism of infection and the molecular mechanisms
underlying the establishment and maintenance of HIV-1 latency
in microglial cells (Garcia-Mesa et al., 2017; Alvarez-Carbonell
et al., 2019). Evidence that the virus was detected in the CSF in
patients under effective cART who had otherwise undetectable
plasma HIV-1 also argues in favor for the production of HIV-
1 in the brain (Edén et al., 2010, 2016; Ferretti et al., 2015).
In addition, phylogenetic analyses also suggest an important
compartmentalization of HIV-1 in the CSF even early in infection
(Salemi and Rife, 2016; Bavaro et al., 2019).
Finally, infection of microglial cells is clearly demonstrated in
animal models such as the macaque and the humanized mouse
(reviewed in Kumar et al., 2016; Marsden and Zack, 2017; Gama
et al., 2018; Abreu et al., 2019). In these models HIV-1 DNA,
RNA and protein were detected in the brain. Importantly, studies
on these models showed that the viral reservoir is established
very early at 3 days post infection (Whitney et al., 2014). More
interestingly, there is evidence that microglial cells can be latently
infected (Avalos et al., 2017; Gama et al., 2017). A macaque
model has recently been designed and a mechanism for the
establishment of HIV-1 transcription suggested (Barber et al.,
2006). In this model, microglial cells can be reactivated in
response to cytokine stimulation (Qin et al., 2015; Xu et al., 2017).
Interestingly, in a cell model developed in Karn’s laboratory, the
glucocorticoid receptor and the toll-like receptor 3 appeared to be
crucial receptors for HIV-1 activation (Alvarez-Carbonell et al.,
2017, 2019). In brain autopsies from patients whose infection
was controlled HIV-1 DNAs in microglial cells and macrophages
were also detected (Thompson et al., 2011; Desplats et al., 2013).
Humanized mouse models were generated in which microglial
cells were infected by HIV-1 in vivo (Asahchop et al., 2017;
Llewellyn et al., 2018; Mathews et al., 2019; Su et al., 2019). These
models will allow us to study the pathophysiology of microglial
cell activation and to develop strategies aiming to reduce the pool
of these reservoirs.
Altogether, there are now numerous evidence supporting
that microglial cells constitute a major cellular reservoir
in the brain. Perivascular macrophages might also be
considered as a cellular reservoir but not a true lifelong
existing one. Moreover, we might expect to reduce drastically
this pool by intensifying cART or by preventing the
transmigration of infected monocytes into the brain. Concerning
astrocytes it is still debated whether they constitute a true
reservoir (Al-Harti et al., 2018; Ko et al., 2019).
Thus, a complete understanding of the molecular mechanisms
underlying establishment and persistence of HIV-1 latency in
microglial cells is needed in order to design original strategies
aiming to target these reservoirs.
ESTABLISHMENT AND PERSISTENCE OF
HIV-1 LATENCY IN MICROGLIAL CELLS
Infection and the constitution of a microglial cell reservoir might
occur very early in the evolution of HIV-1 infection (Whitney
et al., 2014). Some features of the microglial cells allow for the
persistence of HIV-1 in the brain. When infected they are far
more resistant to cytopathic effects and on the contrary of CD4+
T cells they are non-lytic. In addition, these cells are resistant
to apoptosis. The mechanism of apoptosis resistance to HIV-1
deserves considerable attention since it helps to design alternative
strategies based on the increase of apoptosis susceptibility
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(Kumar et al., 2014). Indeed, strategies aiming to reactivate HIV-
1 from infected cells should consider the problem of resistance
to apoptosis since the reinforced therapy might not be efficient
against the newly productive but non-apoptotic cells. Finally, the
antiretroviral drug efficiency is drastically reduced in anatomical
and pharmacological sanctuaries such as the brain where
microglial cells are mostly found and thus contributing also to
viral persistence (Asahchop et al., 2017; Honeycutt et al., 2017).
Two forms of latency have been described which explain HIV-
1 persistence in microglial cells. Latency which occurs before
the integration of the HIV-1 genome into the host is called pre-
integration latency. This form of latency has been frequently
observed in CD4+ T cells and in cells of the monocyte-
macrophage lineage (discussed in Le Douce et al., 2010). In
the latter cells, pre-integration latency might constitute a viral
defense mechanism which could lead to the establishment and
persistence of HIV-1 infection (Cara and Klotman, 2006; Hansen
et al., 2016). This type of latency has not been described in
microglia yet. We call post integration latency when HIV-1
genome has been incorporated into the host DNA genome. The
integrated HIV-1 provirus can then be in an active-replication
state enabling strong transcription of the HIV-1 promoter or in
an inactive-state with amarked repression of HIV-1 transcription
(Pai and Weinberger, 2017; Cao et al., 2018). In CD4+ T cells,
latency is a very rare event with 1 to 106-107 cells being latently
infected (Weinberger andWeinberger, 2013). This rare event has
not yet been described but might occur in the other reservoirs
infected with HIV-1. Mechanisms involved in CD4+ T cell
latency are well-described (Khoury et al., 2018). The strength of
the HIV Tat positive feedback loop regulates principally the viral
fate selection (Figure 1) (Pai and Weinberger, 2017). In other
word, there is stochasticity in HIV-1 transcription which explains
that each single cell differs in many parameters (stage of cell
cycle, level of expression of transcriptional activators/repressors,
metabolic state. . . ). Any mechanism reducing the level of HIV-1
Tat expression under a threshold level might therefore facilitate
the establishment of latency (Karn, 2011). Integration of the viral
genome into repressive heterochromatin environment (Jordan
et al., 2001), transcriptional interference (Han et al., 2008), the
lack of host transcriptional activators (Le Douce et al., 2010;
Churchill et al., 2015), the presence of host transcriptional
repressors (Le Douce et al., 2010; Churchill et al., 2015) or the
influence of viral miRNA on the chromatin environment (Wang
et al., 2009) are thought to favor the establishment of HIV-
1 latency since all these mechanisms significantly decrease the
strength of the Tat positive feedback. Of note, the mechanism
involving viral miRNAs is however controversial and deserves
further studies (Balasubramaniam et al., 2018). Additionally,
post-transcriptional mechanisms regulating reactivation from
latency have also been proposed (Sarracino et al., 2018). On
the other hand, in microglial cells host transcription factors
that facilitate the establishment of latency have been described.
Intriguingly, it was observed that a new CNS strain of the virus
has evolved with specific promoters (the 5’ long terminal repeat
or 5′ LTR) probably due to the compartmentalization of the
virus in the brain (Churchill et al., 2015; Gray et al., 2016).
Moreover, in contrast to other reservoirs, the NF-κB and the core
region including Sp1 sites are sufficient for HIV-1 transcription
in microglial cells (Rohr et al., 2003b). In particular, Sp1 proteins
allow the anchorage of many transcriptional activators such as
NF-IL6 also referred as liver-enriched transcriptional activator
protein (LAP), CREB and Coup-Tf (Figure 1). Unlike CD4+ T
cells which express only Sp1, microglial cells express both Sp1
and Sp3 which operate as transcriptional repressors. In addition,
we and others have shown that in macrophages and microglial
cells, a truncated form of NF-IL6, liver-enriched transcriptional
inhibitory protein (LIP) and/or C-EBPγ is expressed and acts as
repressor by competing with the transcriptional activator NF-IL6
(Schwartz et al., 2000) and (Tesmer and Bina, 1996). Noteworthy,
this latter mechanism explains HIV-1 latency in microglial
cells of a macaque model (Barber et al., 2006). Epigenetic
regulation is also involved in the establishment of latency. Coup-
TF interacting protein 2 (CTIP2 also known as BCL11b) is
a key factor in promoting the formation of heterochromatin,
the compact-inactive form of the promoter, in microglial cells.
Indeed, CTIP2, apart its crucial role in establishing latency, is
also involved in the persistence of latency by preventing HIV-1
reactivation, and in the generation of a cell microenvironment
favorable to the establishment of HIV-1 latency. In addition,
CTIP2 is described as an anti-apoptotic protein (Kamimura
et al., 2007) and thus might also be involved in the apoptosis
resistance in microglial cells (Le Douce et al., 2010; Kumar et al.,
2014). Interestingly a new mechanism to prevent apoptosis in
infectedmacrophage/microglia cells which survived the infection
and became latently infected has been described (Castellano
et al., 2017). They notably showed that apoptosis is blocked at
a very early step and that the pro-apoptotic protein BIM which
accumulate into mitochondria might serve as a new bio-marker
of latently-infected macrophage/microglia cells in vivo.
CTIP2 is a Zinc finger transcription regulator which has
been implicated in many functions required during development
and in adult animal (reviewed in Le Douce et al., 2014).
Germline disruption of CTIP2 is mortal stressing its importance
during development. In fact, the essential role of CTIP2 in T
cell development, odontogenesis, skin development and neuronal
development are now well-documented (Le Douce et al., 2014).
It was shown that CTIP2 is a transcriptional regulator binding
directly on a promoter specific sequence (Avram et al., 2002) or
binding indirectly to other promoter-bound transcription factors
such as Sp1 (Avram et al., 2000).
CTIP2 is involved in the establishment of HIV-1 latency
by favoring the formation of heterochromatin in the vicinity
of the viral promoter. It serves as a platform anchoring a
chromatin modifying complex (Marban et al., 2007). Indeed,
our work showed that in the presence of CTIP2 histone
deacetylases HDAC1, HDAC2, and histone methyltransferase
(HMT) SUV39H1are simultaneously recruited on the viral
promoter which generates the H3K9me3 epigenetic mark
(trimetylation of H3K9) (Figure 2). This work was the first
to demonstrate the recruitment of HMT at the latent HIV-
1 promoter. It paved the way for reactivation strategies that
use a combination of molecules targeting multiple enzymatic
activities. Furthermore, we characterized a new factor working
in synergy with CTIP2 i.e., the lysine specific demethylase 1
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FIGURE 1 | Stochasticity of transcription in microglial cells. The provirus (in yellow) integration in the genome of the microglial host cell (in gray) leads to two possible
fates of the cell: active or latent. In active cells, Sp1 allows the anchorage of transcriptional activators like NF-IL6, CREB, and Coup-Tf. It enhances Nf-κB activity and
allows the transcription of the viral transactivator Tat in the early phase of transcription. Then, Tat promotes the recruitment of active p-TEFb elongation complex at
TAR regions. This recruitment allows viral RNA elongation and transcription activation during the late phase. It results a Tat production which promotes a Tat positive
feedback loop and enables a strong transcription of the HIV-1 promoter. In the early phase in latently infected microglial cells, Sp3 act as a transcriptional repressor. In
addition, C-EBPγ competes with the transcriptional activator NF-IL6. These repressors reduce Tat expression, p-TEFb recruitment, and viral RNA elongation during
the late phase of transcription. If Tat production is under a threshold level, transcription is inhibited and the virus is inactive.
(LSD1), which we showed to be a key factor in the molecular
mechanisms of establishment of HIV-1 latency (Le Douce et al.,
2012). In particular we established that LSD1 inhibits HIV-
1 transcription and viral expression by recruiting hSet1 and
WDR5 on the HIV-1 promoter, two members of the hCOMPASS
complex, which induce H3K4me3 epigenetic mark (trimetylation
of H3K4) (Figure 2). The association of H3K4me3 andH3K9me3
epigenetic marks might represent a new level of eukaryotic
gene regulation. It was suggested that gene repression linked
to H3K4me3 prevents the expression of cryptic promoters
(Pinskaya and Morillon, 2009). This is supported by the findings
that HIV-1 better integrates in active genes and thus can be
considered as a cryptic gene (Wang et al., 2007).
Recently, we showed that CTIP2 is in another complex,
which is able to counteract HIV-1 reactivation. In the initial
report it was suggested that CTIP2 represses, the Tat-dependent
late phase of HIV-1 transcription (Rohr et al., 2003a). Later
experiments showed that an inactive form of the elongation
factor pTEFb is recovered in a complex containing the non-
coding 7SK snRNA and the proteins CTIP2 and HEXIM1 are
attached to viral and cellular gene promoters in the absence of
the HIV-1 factor Tat (Cherrier et al., 2013). pTEFb is a dimer
comprising a regulatory subunit CyclinT1 and a catalytic subunit
CDK9. CDK9 is a kinase which phosphorylates the Ser2 residue
of the carboxyl terminal end of the RNA polymerase II and
the negative transcriptional elongation factors NELF and DSIF.
We showed that in this complex CTIP2 significantly inhibited
CDK9 kinase activity thus inhibiting pTEFb function (Cherrier
et al., 2013). In a following paper, we showed that the cellular
protein High Mobility Group AT-hook 1 (HMGA1), which
also belongs to the 7SK snRNA complex, recruited the inactive
CTIP2/pTEFb complex onto the HIV-1 and cellular target
promoters thus regulating their gene expressions (Eilebrecht
et al., 2014). HMGA1 has been previously shown to interact with
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FIGURE 2 | Establishment and persistence of HIV-1 latency in microglial cells: CTIP2 as a central actor. (Left) CTIP2 is involved in the establishment of HIV-1 latency
by recruiting a chromatin modifying complex at the viral promoter (HIV-1 LTR). CTIP2 is anchored at Sp1 sites on the viral promoter and act as a scaffolding for the
recruitment of several chromatin modifying proteins. They perform epigenetic modifications of histones of the nucleosome located at the promoter. CTIP2 recruits
simultaneously HDAC2, HDAC1 and the HMT Suv39H1. HDAC1 deacetylate histones while Suv39H1 generates the trimethylation of H3K9 (H3K9me3). In addition,
LSD1 promotes the trimethylation of H3K4 by the hCOMPASS methyltransferase complex through hSet1 and WDR5 recruitment. These two epigenetic marks are
sufficient to promote chromatin compaction (heterochromatin) and inhibit transcription. (Right) CTIP2 prevents transcription restart by sequestrating the elongation
factor pTEF-B in an inactive complex. 7SK snRNA complex is recruited at promoter via HMGA1 by interaction with transcription factors (TF). HMGA1 then recruits
CTIP2 associated with the inactive form of PTEF-B (Cyclin T1 and CDK9) and HEXIM1, on the 7SK snRNA. Transcription is inhibited at two levels. First, CTIP2 inhibits
the kinase activity of CDK9, a pTEF-B subunit which prevent RNA pol II activation by inhibiting the phosphorylation of RNA pol II and the two subunits NELF and DSIF.
Second, the persistence of inactive pTEF-B at the promoter prevents any recruitment of active pTEF-B.
TAR to modulate Tat-dependent HIV transcription (Eilebrecht
et al., 2013). It seems that HMGA1 is critical for the repressive
function of CTIP2. We propose a model in which HMGA1
facilitates the recruitment of CTIP2-inactivated P-TEFb onto
cellular and viral gene promoters (Figure 2).
As suggested above, CTIP2 has an important role in the
regulation of the expression of many infected cells genes.
Microarray analysis of a microglial cell line knocked down for
CTIP2 showed up or down regulation of several genes (Cherrier
et al., 2013). Among them the cellular cyclin-dependent kinase
inhibitor CDKN1A/p21waf was up regulated. When recruited
to the p21 promoter, CTIP2 represses p21 gene transcription
with the same mechanism described for the HIV-1 promoter
(Cherrier et al., 2009). The p21 gene repression may favor HIV-1
latency since activation of p21 gene stimulates viral expression
in macrophages (Vazquez et al., 2005). In addition, CTIP2
counteracts HIV-1 Vpr which is required for p21 expression.
Interestingly we recently showed that HIV-1 Vpr mediates the
depletion of the cellular repressor CTIP2 to counteract viral
gene silencing (Forouzanfar et al., 2019). Altogether our findings
strongly support the findings that CTIP2 generates a cellular
environment which is favorable for HIV-1 latency. Furthermore,
our results support that CTIP2 is a major actor involved in HIV-1
latency in microglial cells. In agreement with our findings, CTIP2
colocalized with the microglial marker Ionized calcium binding
adaptor molecule 1 (Iba1) in latently infected patients but not
in HIV encephalitis (HIVE) patients (Desplats et al., 2013).
Moreover, the levels of CTIP2 and markers of heterochromatin
such as HDACs and heterochromatin 1 (HP1) were increased in
microglial cells from HIV-1 positive latent cases. This work and
others suggested that CTIP2 can be used as an HIV brain latency
biomarker (Cysique et al., 2019).
Recently we have identified and characterized a new cellular
factor i.e., Hypermethylated in Cancer 1 (HIC1). This factor
regulates together with CTIP2 and HMGA1 cellular and HIV-
1 gene transcriptions (Le Douce et al., 2016). However, the
repressive activity of the complex requires the deacetylase activity
of Sirtuin 1 (SIRT1) in microglial cells. We showed that HIC1
interacted and cooperated with HMGA1 and modulated Tat
dependent HIV-1 transcription. However, intriguingly it occurs
in the presence of Tat but it is independent of the elongation
factor PTEFb. The need for HMGA1 to interact with HIC1 to
repress the Tat dependent HIV-1 transcription might suggest a
new role for HMGA1 in this process (discussed in Le Douce et al.,
2016). Our findings support the idea that the TAR element serves
as a HIC-1 reservoir to promote HIC-1/Tat interaction.
We are far from elucidating all the molecular mechanisms
which underlie HIV-1 latency in microglial cells. Further
investigation in this field is needed in order to identify new
potential targets in HIV-1 therapy.
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TARGETING THE MICROGLIAL CELLS
Targeting all the HIV-1 reservoirs including the microglial cells
in the brain is important in order to achieve either a sterilizing
or a functional cure. Indeed, these cells are potential sources of
HIV-1 reseeding in the blood. In addition, production of the
virus in these cells has been associated with HIV-1 resistance and
the development of HAND. However, targeting these cells which
are located in anatomic and pharmacologic sanctuaries might
be very challenging (Marban et al., 2016). Most importantly the
access of drugs used in cART is limited by the blood brain
barrier. Poor access of the drugs contributes to the persistence
of HIV-1 in microglial cells (Cosenza et al., 2002). Another
limitation is the existence of a residual neuroinflammation which
is responsible for the occurrence of HAND in up to 50% of HIV-
1 infected patients. A main concern is to prevent deleterious
neuroinflammation associated with infected microglial cells
(Rock and Peterson, 2006). To date, three strategies are used
to target infected microglial cells (Veenhuis et al., 2019): (i)
the Shock and Kill strategy, (ii) the Block and Lock strategy,
and (iii) gene therapy. We will discuss in the following section
the principles of these three approaches and outline their
limitations. Finally, we briefly discuss how these limitations
can be circumvented and how to rationalize treatments aiming
the eradication or reduction of the pool of latently infected
microglial cells.
Strategies to Struggle Latently-Infected
Microglial Cells
The Shock and Kill Strategy
The Shock and Kill strategy is based on the reactivation of
the latent virus. In this strategy the intensification of cART
aims to clear the reservoirs either by the cytopathic effect of
the reactivated virus or by the immune system via the actions
of cytotoxic T cells (CTLs) (Schwartz et al., 2017). Latency
reversing agents (LRAs) used in the reactivation target identified
and characterized cellular factors involved in HIV-1 latency
(Figure 3). Many LRAs are now used ex vivo and in clinical
trials. However, the main targets are circulating CD4+ T cells
and not the microglial cells (Kumar et al., 2015; Spivak and
Planelles, 2018). There are currently 160 compounds used as
LRAs which belong to two main families or to a third one
which includes uncommon drugs with unique or unknown
mechanisms (e.g., disulfiram and ixazomid) (Abner and Jordan,
2019). Screening of new LRAs is still a field of intensive research
(Richard et al., 2018).
One family of LRAs targets epigenetic mechanisms that
occur in latency (Darcis et al., 2016). This class comprises
HDAC inhibitors (HDACi) such as Valproic acid, Vorinostat,
panobinostat, and romidepsin; Histone methyl transferases
inhibitors (HMTi) such as chaetocin and BIX 01294; and DNA
methylation inhibitors such as 5-AzadC.
In the second family T cell activating agents are listed. These
drugs induce the expression of positive cellular factors and/or
their release from inactive complex (Jiang and Dandekar, 2015;
Rice, 2016). Prostratin, bryostatin, and ingenol B by activating the
PKC pathway release NF-KB and pTEFb from inactive complexes
and increase pTEFb expression (Sung and Rice, 2006; Fujinaga
et al., 2012; Pandeló José et al., 2014) which leads to HIV-1
reactivation (Darcis et al., 2015). Bromodomain inhibitors such
as JQ1 and others are able to release pTEFb from the BRD4-
pTEFb complex (Bartholomeeusen et al., 2012; Li et al., 2013;
Darcis et al., 2015). Many other compounds including TLR
agonists, TNFα, cytokines, and antibodies are also used as LRAs.
A comprehensive review of these compounds are described
elsewhere (Abner and Jordan, 2019).
However, these drugs used alone failed to fully reactivate
HIV-1 expression ex vivo (Cary et al., 2016; Darcis et al., 2016).
This might reflect the multi factorial mechanisms involved in
promoting latency and the stochastic nature of latency (Sengupta
and Siliciano, 2018). Another important inability of LRAs relies
in their lack of specificity and to the heterogeneity of the
reservoirs (Ait-Ammar et al., submitted). Indeed, the LRAs are
mainly used in clinical assays to target circulating CD4+ cells
but not the other reservoirs such as microglial cells. Therefore,
combination of LRAs is now used to circumvent these problems.
We expect synergistic effect which improves the efficiency of
reactivation and reduces toxicity because of the lower doses used.
Moreover, a recent report demonstrated the importance of the
timing of the LRA combination treatment in the reactivation of
HIV (Bouchat et al., 2016).
Reactivation of reservoirs should be followed by the
elimination of the virus (Kim et al., 2018). There is now
evidence that eradication of latently-infected reservoirs in
patients involves humoral and cell mediated immune responses
(Schwartz et al., 2017). Humoral immune response plays an
important role in controlling HIV infection (reviewed in Ferrari
et al., 2017). Over the past years, a new class of antibodies,
called broadly neutralizing antibodies, have been shown to
neutralize a wide range of HIV strains (Halper-Stromberg and
Nussenzweig, 2016). Preclinical studies in which SHIVs infected
macaque monkeys and HIV-1 infected humanized mice were
treated by antibodies gave promising results (Halper-Stromberg
and Nussenzweig, 2016). The efficacy of the treatment was
even enhanced when various broadly neutralizing antibodies in
combination was applied (Bruel et al., 2016) or when using
multi-specific engineered antibodies like bi and tri-specific
antibodies (Ferrari et al., 2016; Sun et al., 2016). Numerous
strategies were proposed to enhance cell-mediated immune
responses, e.g., CD8+ T cell or natural killer cell activities
(Scully and Alter, 2016; Trautmann, 2016). Some methods aim
to redirect HIV-specific cell mediated immune responses (Patel
et al., 2016). In one strategy, redirected T cells recognizing
a range of HIV antigens are expanded ex vivo. In another
strategy genetically modified lentiviruses expressing artificial T
cell receptors (TCRs) or chimeric antigen receptors (CARs)
are used in the treatment (Patel et al., 2016). Increasing the
specificity and the affinity of the epitopes of the receptors to
achieve wider HIV epitope recognition is also realistic (Patel
et al., 2016). The possibility to increase HIV-specific CD8+
T cell responses with heterocyclic peptides is currently tested.
It is assumed that these peptides stimulate deeper the cell-
mediated immune responses than native epitopes (Buhrman
et al., 2013).
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FIGURE 3 | Strategies to struggle latently-infected microglial cells. The shock and kill: the strategy is based on the reactivation of virus expression, in order to
eliminate reservoirs and to target latently-infected cells. Latency reversing agents (LRAs) are investigated to reactivate transcription for the “shock.” A first family of
LRAs are HDAC, HMT, or DNA Mtases inhibitors and target epigenetic mechanisms. These LRAs induce chromatin decompaction and promote virus transcription.
Another family of LRAs induce the expression of positive cellular factors (e.g., NF-κB and pTEFB) and/or their recruitment under their active form. These LRAs
promote ARN pol II recruitment and favor transcription. The cART is maintained during this phase to clear reservoir without virus propagation in other cells. The “kill”
can be enhanced by stimulation of the cell-mediated immune response or by using neutralizing antibodies and/or engineered antibodies. The block and lock: this
strategy relates on the induction of a state of deep-latency which prevents any HIV-1 transcription. Several latency-promoting agents (LPAs) are investigated. They
inhibit various step of virus expression like replication, transcription by Tat inhibition and RNA export. One promising LPA is a miRNA which inhibit virus expression. The
gene therapy (CRISPR-Cas9): this strategy is based on the use of molecular scissors to excise total, or more reasonably, partial sequence of the provirus. Another
strategy would be to use deficient Cas9 (dCas9) to carry reactivators or repressors of HIV-1 expression.
An original approach took advantage of the importance
of co-stimulatory and co-inhibitory molecules involved in the
regulation of T-cell responses (Sharpe and Abbas, 2006). Indeed,
treatment by specific antibodies targeting the co-inhibitory
molecule PD-1 is thought to reduce the size of the latently-
infected reservoir and help to recover CD8+ T cell function from
collapse. Finally, therapeutic vaccines might help CTLs to target
HIV-1 infected cells derived from latent reservoirs (Deng et al.,
2015).
The Block and Lock Strategy
An alternative approach to achieve long term control over HIV-1
infection without the need of cART is to induce a long lasting
inhibition of HIV-1 gene expression (Figure 3) (Darcis et al.,
2017). The molecules used to induce this process are called
latency-promoting agents (LPAs). LPAs are expected to suppress
the HIV-1 gene expression by inducing a deep latency state (the
block) and thus preventing HIV-1 gene transcription (the lock)
(Elsheikh et al., 2019). The first LPA identified from a marine
sponge is a chemical derivative of corticostatin i.e., Didehydro-
corticostatin (dCA). It inhibits Tat activity by preventing Tat-
TAR interaction (Mousseau et al., 2015). To date many other
LPAs have also been described (reviewed in Castro-Gonzalez
et al., 2018). One of them, the ABX464, an inhibitor of Rev
which is involved in the RNA export blocks HIV-1 replication
in vitro as well as in animal models (Campos et al., 2015).
Cellular mi RNAs are also potential molecules to be used in
the Block and Lock strategy. It has been known for a long time
that miRNAs are important modulator of HIV-1 latency (Huang
et al., 2007). Screening and computational analysis have allowed
the characterization of many miRNAs which impact HIV-1
transcription. One such promising miRNA, i.e., miRNA29a,
which inhibits the virus transcription in Jurkat cells should be
investigated for its effects in microglial cells (Hariharan et al.,
2005). It is suggested that inducing miRNA29a expression in
these cells could lead to suppression of HIV-1 gene expression.
The Gene Therapy
Gene therapy has been widely considered as a tool to combat
HIV-1. It relies on nuclease-mediated gene editing tools such as
the zinc fingers nuclease (ZFN1), the transcription activator-like
effector nucleases (TALEN) and the CRISPR/Cas9 technologies
(Panfil et al., 2018; Wang et al., 2018). Various gene therapies
have been launched since the sterilizing cure of the Berlin patient
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 9 October 2019 | Volume 9 | Article 362
Wallet et al. HIV-1 Reservoir in the Brain
(Allers et al., 2011). This patient received transplantation of
hematopoietic stem cells from a donor who was homozygous
for the CCR5-delta32 mutation (1CCR5) conferring resistance
to HIV infection. Recently a second patient who shared similar
medical contexts, the London patient, was also cured from HIV-
1 infection (Gupta R. K. et al., 2019). From this example, the
idea to build HIV-1 resistant cells has arisen (Barmania and
Pepper, 2013). Clinical trials using ZFN targeting CCR5 are
ongoing and deserve attention (Mehta et al., 2017). However, The
CRISPR/Cas9 gene editing has become the tool of choice, since
ZFN and TALEN are costly and time consuming. This tool uses
a guided RNA and a Cas9 nuclease that excise DNA sequences
of target specific cellular factors such as CCR5 or HIV-1 DNA
thus eliminating the HIV-1 provirus (Figure 3). The first targeted
DNA sequence by the CRISPR/Cas9 technology was the NF-
KB binding site located in the HIV-1 LTR (Ebina et al., 2013).
Since then, many other HIV-1 sequences have been targeted
(Xiao et al., 2019). This technology may serve to redesign the
gene expression of cells such as CTLs so that they target more
specifically HIV-1 infected cells. It is believed that by this way
the antiviral immunity system could be more efficiently boosted
against HIV-1 infected cells and activated reservoirs producing
new virions (Mehta et al., 2017).Wemight even use a variation of
the CRISPR/Cas9 technology to reactivate latently infected cells
or to induce deep latency (Wang et al., 2018). For this purpose, a
defective Cas9 (dCas9) protein is fused to activators to reactivate
latently-infected cells (Figure 3) or to repressors to suppress
HIV-1 expression (Wang et al., 2018). In vitro trials suggested
a potential application of CRISPR/dCas9 in the reactivation of
latent HIV (Zhang et al., 2015). These trials showed reactivation
of HIV expression in CD4+ T cells and in microglial cell lines
(Cary and Peterlin, 2016). Interestingly, CRISPR/dCas9 when
associated with HDAC inhibitors and PKC activators reactivated
HIV in a synergistic manner (Limsirichai et al., 2016).
Limitations and Challenges When
Targeting Brain Microglial Cells
The current therapeutic strategies have limited efficacy to
achieve cure. Their limitations comes from (i) the intrinsic
nature of the strategy, (ii) the nature of the cells targeted, or
(iii) the attributes of the virus to escape antiviral responses.
Regarding microglial cells their specific cell properties and
their location in anatomical and pharmacological sanctuaries
make them difficult to target. In consequence, the presence
of the BBB drastically reduces drug access to currently used
drugs in cART (Asahchop et al., 2017). New antiviral drugs
with improved CNS penetrance have been introduced in the
last years (Veenhuis et al., 2019). However, some showed
important side effects. For example, a new integrase inhibitor
which showed important CNS uptake (Letendre et al., 2014)
was neurotoxic showing severe neuropsychiatric effects (Scheper
et al., 2018). Various technics improving delivery of drugs in
the CNS and in the CNS-cell types are currently explored.
Mechanisms underlying weak drug penetrance are mainly related
to differential expression of efflux transporter and to multidrug
resistance proteins (Valcour et al., 2011; da Fonseca et al.,
2014). Several invasive and non-invasive methods for drug
delivery are currently explored including modulation of brain
barrier, ultrasound based BBB opening, endogenous transporter,
nanoparticles, liposomes, dendrimers. . . (reviewed in Barnabas,
2019). Original route of drug delivery to the CNS are also
explored such as drug delivery from the nose to the brain (Gupta
S. et al., 2019).
We should also consider immune-based therapeutics to clear
reservoirs activated by the LRAs. Animal models have shown
the importance of the CTLs and neutralizing antibodies raised
against HIV-1 in immune activation and clearing infected
reservoirs in the CNS. Therefore it deserves considerable
attention to ensure the feasibility of the Shock and Kill strategy
(Brockman et al., 2015; Trautmann, 2016; Subra and Trautmann,
2019).
An important limitation of the use of the Shock and Kill
strategy is that reactivation of microglial cells during the Shock
therapy leads to neuroinflammation, since the release of pro-
inflammatory factors and some viral proteins such as Tat and
gp120 during the shock therapy are neurotoxic. Therefore, LRAs
induced reactivation of reservoirs has to be associated with
drugs preventing the adverse effects of neuroinflammation. One
way to prevent inflammation is to improve cART via targeting
HIV-1 transcription and/or by inhibiting RNA export in order
to counteract the effects of the pro-inflammatory cytokines
and to prevent synthesis of viral proteins (Schwartz et al.,
2017). Molecules which have anti-inflammatory effects such
as curcurmin are also investigated in microglial inflammatory
responses (Chen et al., 2018). A new drug formulation using
lipid nano-carrier and administration by intra nasal route are
currently investigated (Vaz et al., 2017). Remarkably, many drugs
targeting the NF-κB pathway (G1V001), the protein Tat (dCA,
triptolides. . . ) and rev (ABX4641) induce a deep latency and
are thought to be used in the Block and Lock strategy as an
alternative to the Shock and Kill strategy. We might use both
strategies in a sequential time schedule. First, the Shock and Kill
strategy which reactivates and decreases the pool of reservoirs.
Followed by application of drugs exploiting the Block and Lock
strategy, which suppresses transcription in persisting reservoirs
and induces deep latency. Although, it is still an emerging field
of research the Block and Lock strategy appears to be more
than just an alternative to other strategies. Interestingly, less
adverse effects with drugs targeting viral proteins are awaited.
We believe that combination of the Block and Lock strategy
with the Shock and Kill might allow the reduction of all
HIV-1 reservoirs, including the microglial cell reservoir to a
level, which does not need any further treatment to achieve a
functional cure.
Gene therapy compared to a pharmacological approach
such as the Shock and Kill strategy is still in its infancy but
appears to be very promising. A recent review compares the
advantages and weaknesses of these two approaches i.e., the
pharmacological vs. CRISPR/Cas9-based shock strategies (Darcis
et al., 2018). Gene therapy, in the same way as pharmacological
approaches, does not resolve the problem of drug penetrance
in the CNS where microglial cells are located. Indeed, currently
used adeno-viruses in in vitro essays induce severe inflammation
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(Chew et al., 2016). Moreover, another important limitation of
gene editing was discovered; HIV-1 can escape CRISPR/cas9
mediated suppression. Indeed, following an initial attempt to
establish proof of concept of the use of gene editing targeting
specifically HIV-1 (Kaminski et al., 2016), it soon appeared
that the virus was able to subvert the DNA repair machinery
to evolve quickly into CRISPR/Cas9 resistant strains (Liang
et al., 2016; Wang G. et al., 2016; Wang Z. et al., 2016;
Yoder and Bundschuh, 2016). On the other hand combination
of guided RNAs targeting different HIV-1 specific sequences
may drastically reduce the occurrence of HIV-1 escape (Wang
et al., 2018). A major off-target of this gene editing tool is
the increase of undesirable gene mutations and chromosomal
translocations (Yee, 2016). Efforts in reducing these off-target
effects are required in order to improve this elegant and
attractive approach. For example, bioinformatics could help to
select the correct guided RNAs that avoid unexpected DNA
cleavage (Zhu et al., 2017). Another limitation of the use of
gene editing technology is that it has been mainly tested in
vitro and mainly in CD4+ T cells. Experiments conducted ex
vivo showed that redirected immune cells reached only a tiny
fraction of the HIV-1 reservoirs. Therefore, this technology does
not make possible to drastically reduce the number of infected
cells, which is required to achieve functional cure (Wang et al.,
2018).
Rationalization of these strategies is required to optimize
either of these strategies to target microglial cells. Since we
cannot make brain biopsies due to ethical concerns, it is critical
to design these strategies and test their feasibility in adequate
animal models. Indeed, the efficacy and the pharmacokinetic
and pharmacodynamic characteristics of drugs are tested only in
preclinical studies. Non-human primates (NHP) and humanized
mice are currently the best-suited animal models to study
either strategies. However, there are many ways to evaluate the
efficiency of a therapy and to evaluate HIV infection in the brain.
The search of specific biomarkers for latently infected microglial
cells may lead to the development of original strategies, which
specifically target brain reservoirs. One such specific marker of
the CD4+ T cell reservoir, CD32a, has been described (Descours
et al., 2017), although its specificity is debated (Badia et al.,
2018). Much research has been focused on finding new specific
biomarkers for brain reservoirs, nonetheless their use will be very
challenging. Indeed, it will be difficult to target brain reservoirs
ex vivo, even though it is technically possible for blood cells,
and very difficult to target them in vivo due to their paucity and
localization in the entire brain parenchyma. For example, the
invasive techniques used to evaluate the evolution of biomarkers
in the CSF such as neopterin, CTIP2, TREM2, and NFL after
a treatment cannot be performed too frequently (Jessen Krut
et al., 2014). Non-invasive methods such as neuroimaging are
therefore needed for brain evaluation (discussed in Garrido and
Margolis, 2015). Comprehensive neuropsychological testing is
also required to detect subclinical deficits (Haddow et al., 2013).
It will be essential to evaluate the efficiency of each strategy
that target microglial cells. For this purpose, highly sensitive
methods have been developed such as the single copy assay
(SCA) which allows the detection of HIV RNA in the CSF
from infected patients on cART or from elite controllers whose
HIV RNA level was initially undetectable in the plasma and the
CSF (Dahl et al., 2013).
CONCLUSION
HIV cure is theoretically possible but not yet feasible with
current approaches. Complete cure demands targeting not only
the CD4+ T cells reservoirs but also all the other potential
reservoirs located in sanctuaries with low drug penetrance. This
is particularly true for the microglial cells in the CNS which
is considered as the main reservoir for HIV. Indeed, due to
their properties (slow turn over, long half-life. . . ), these cells
are thought to persist lifelong. Other true reservoirs such as
macrophages may be eliminated by intensifying cART and/or
by targeting HIV infected monocytes which is the source of
infection. Other reservoirs such as astrocytes or the newly
identified pericytes (Bertrand et al., 2019) may constitute true
reservoirs, but these are still debated and deserve far more
investigations. Currently, three strategies are considered, which
allow functional cure: two pharmacological approaches including
the shock and kill strategy and the alternative block and lock
strategy and the CRISPR/cas9 based technology, which is a
gene editing tool based strategy. However, the Shock and Kill
strategy is not suitable to eliminate reservoirs like microglial
cells, since the reactivation of microglial cell reservoirs leads to
neuroinflammation, which is the origin of HAND. The search
for potential epigenetic regulators that control microglial cells
are therefore needed. The most investigated epigenetic regulators
are the long non-coding RNAs (Qu et al., 2019) and the mi
RNAs (reviewed in Cheray and Joseph, 2018). However, due
to the stochasticity of HIV-1 transcription the Shock and Kill
strategy does not allow reactivation of all latently infected
microglial cells. Alternative strategies are therefore considered.
The Block and Lock strategy has the advantage that the risk
of inflammation in the brain is drastically reduced. More
importantly, this strategy since it targets transcription and/or
RNA export might be used following the Shock and Kill strategy.
The combination of strategies should lead to the decrease of
the pool of the microglial reservoir. It may also induce deep
latency in reservoirs that are not reactivated by LRAs. The
gene editing tool, such as the CRISPR/Cas9 technology, because
it operates on specific sequences is also very promising. Still
in its infancy, this elegant approach can target either cellular
factors, which are involved in HIV-1 resistance, or viral factors.
This technology can be used either to reactivate the virus or
to excise and eliminate the provirus from its host genome.
However, several challenges have to be overcome such as in
vivo delivery in the brain and long-term toxicity before its
use in the clinic and thus needs far more investigations. An
original way to deliver CRISPR/cas9 guided RNA across the
BBB has been developed recently and hold promises (Kaushik
et al., 2019). Notably, it was shown that this non-invasive
methodwhich usesmagnetically guided delivery of RNAs inhibits
latent infection of microglial cells and cross the BBB in in
vitromodels.
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In conclusion, targeting microglial cells is crucial but might
be very challenging. We have to keep in mind that these cells
are resistant to the cytopathic effects of the virus and resistant to
apoptosis. Thus strategies aiming to induce apoptosis in infected
microglial cells have to be developed (Le Douce et al., 2010).
It appears that the cellular factor CTIP2 (Bcl11b) has a pivotal
role in the establishment and persistence of HIV latency, in
the genesis of a favorable environment for HIV latency and
in the resistance to apoptosis (Le Douce et al., 2014). CTIP2
silencing by RNA interference has been proposed in cancer
since downregulation of CTIP2 leads to apoptosis in malignant
cells but not in normal mature cells (Grabarczyk et al., 2007;
Huang et al., 2007). We might also design drugs targeting CTIP2
interacting proteins specifically involved in HIV-1 latency and
apoptosis resistance. Moreover, establishing a protein interaction
network focused on CTIP2 interactions in microglial cells will
allow the identification and characterization of new actors
involved in HIV-1 latency and apoptosis resistance.
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